Cost Effectiveness of Apixaban (Novel Oral Anti-Coagulant) Compared with Conventional Therapy for Stroke Prophylaxis among Renal Impaired Patients with Atrial-Fibrillation from Perspective of Us Third Party Payer
May 1, 2016, 00:00
10.1016/j.jval.2016.03.112
https://www.valueinhealthjournal.com/article/S1098-3015(16)00180-7/fulltext
Title :
Cost Effectiveness of Apixaban (Novel Oral Anti-Coagulant) Compared with Conventional Therapy for Stroke Prophylaxis among Renal Impaired Patients with Atrial-Fibrillation from Perspective of Us Third Party Payer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)00180-7&doi=10.1016/j.jval.2016.03.112
First page :
A47
Section Title :
Cardiovascular Disorders - Cost Studies
Open access? :
No
Section Order :
1445